Abstract
BackgroundCurrently, only a fraction of patients with non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors (ICIs) experience a durable clinical benefit (DCB). According to NCCN guidelines, Programmed death-ligand...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have